chimeric antigen receptor T cell therapy

Overview

Chimeric antigen receptor T cell (CAR-T) therapy is a form of adoptive cell immunotherapy in which a patient's own T lymphocytes — or, in allogeneic settings, those of a healthy donor — are genetically engineered to express a synthetic receptor that directs cytotoxic activity against tumor-associated antigens. The chimeric antigen receptor itself is a fusion construct typically comprising an extracellular single-chain variable fragment (scFv) derived from a monoclonal antibody, transmembrane anchoring domains, and intracellular costimulatory and CD3ζ signaling modules. Upon antigen engagement, the receptor activates downstream T cell effector programs independently of major histocompatibility complex (MHC) presentation, enabling recognition of surface antigens that evade conventional cytotoxic T cell surveillance. Approved products primarily target CD19 (the MS4A1 gene product) and B-cell maturation antigen (BCMA, encoded by TNF receptor superfamily member 17, TNFRSF17), making CAR-T therapy a cornerstone of treatment for relapsed or refractory B-cell malignancies and multiple myeloma.

The therapeutic mechanism depends on robust in vivo expansion, tumor infiltration, and sustained cytotoxicity, all of which can be undermined by T cell exhaustion, antigen loss or heterogeneity, and the immunosuppressive tumor microenvironment (TME). Manufacturing complexity — which involves leukapheresis, ex vivo transduction with lentiviral or retroviral vectors, expansion, and cryopreservation — contributes to treatment delays and high costs. These biological and logistical constraints have spurred active research into next-generation receptor architectures, combination strategies with other immunotherapies, in vivo engineering approaches, and alternative cellular platforms including CAR-NK cells.

Focus of Latest Publications

Hematologic Malignancies: Established Indications and Expanding Frontiers

The most mature clinical evidence for CAR-T therapy remains concentrated in B-cell malignancies and plasma cell disorders. A 2026 systematic review and meta-analysis (PMID 41508418) evaluated CAR-T outcomes specifically in relapsed or refractory multiple myeloma (RRMM), concluding that immunotherapy — and CAR-T therapy in particular — shows significant clinical promise for this patient population. Complementing this, a SEER-based population-level analysis spanning 1975 to 2023 (PMID 42047296) identified inflection points in multiple myeloma mortality that aligned with successive therapeutic innovations, including the introduction of CAR-T cell therapy and bispecific antibodies alongside proteasome inhibitors and immunomodulatory drugs. A 2026 review of data from the 2025 ASH annual meeting (PMID 41975476) further highlighted that CAR-T therapy is rapidly reshaping the multiple myeloma treatment paradigm, with emerging evidence supporting its deployment in first-line settings.

In large B-cell lymphoma (LBCL), axicabtagene ciloleucel (axi-cel) has been studied in the second-line setting. An analysis of early PET response using the Deauville score (PMID 41894687) demonstrated that FDG-PET imaging following second-line axi-cel can predict relapse risk, with the observation that post-CAR-T treatment options are expanding and that timely re-intervention should be considered for patients at high relapse risk. A large retrospective Australian multicenter study of 584 patients receiving CAR-T therapy for LBCL (PMID 41701973) found no significant association between time of infusion and clinical outcomes, arguing against a meaningful chronobiological effect in this setting.

In B-cell acute lymphoblastic leukemia (B-ALL), brexucabtagene autoleucel outcomes were examined in the context of prior therapy resistance (PMID 41643192): lack of response to blinatumomab before CAR-T infusion correlated with significantly worse post-CAR-T survival, highlighting the prognostic weight of prior immunotherapy sensitivity. A five-year follow-up of a phase I trial evaluating zamtocabtagene autoleucel — a CD20/CD19 tandem CAR-T construct — in relapsed/refractory B-cell non-Hodgkin lymphoma (PMID 41512222) noted that relapse rates exceeding 50% remain a challenge after CD19-directed therapy, motivating dual-antigen targeting strategies.

Acute Myeloid Leukemia: Mechanistic and Translational Advances

CAR-T therapy in acute myeloid leukemia (AML) faces distinct obstacles relative to lymphoid malignancies. A 2026 review of preclinical advances (PMID 41800605) characterized CAR-T as a transformative investigational strategy for AML but emphasized that clinical translation is severely impeded by target antigen scarcity and the immunosuppressive TME. The review surveyed target iteration — including identification of antigens with differential expression on leukemic blasts versus normal hematopoietic progenitors — and approaches to reprogramming the TME to support CAR-T persistence and function.

Solid Tumors: Overcoming the Antigen and Microenvironment Barrier

Application of CAR-T therapy to solid tumors remains limited by tumor antigen heterogeneity, poor trafficking, and rapid exhaustion. The CUTE (Clickable Universal Tumor-Antigen Equipping) strategy (PMID 42013422) was developed to address the scarcity of tumor-specific antigens by equipping tumor cells with artificial epitopes recognizable by universal CAR-T cells, demonstrating potent activity against solid tumor models. In glioblastoma multiforme (GBM), a study generating allogeneic CAR-T cells (PMID 42031691) found that allogeneic products could circumvent functional deficits observed in patient-derived autologous material, with clinical trials in GBM targeting various antigens not yet showing durable benefit. CAR-neutrophils engineered in vivo showed complementary efficacy when combined with chemotherapy and CAR-T therapy in glioma models (PMID 42032037). For osteosarcoma, LRRC15-directed CAR-T cells were proposed as a promising approach in relapsed, refractory, or metastatic disease (PMID 41627173).

A key mechanistic challenge — T cell exhaustion — was the focus of multiple studies. Overexpression of the transcription factor KLF4 in CAR-T cells was reported to enhance antitumor potency by preventing exhaustion (PMID 42161404), offering a transcriptional strategy to prolong functional persistence. Separately, engagement of the endogenous T cell receptor (TCR) against an oncolytic virus was shown to generate a population of effector CAR-T cells with potent antitumor activity and reduced exhaustion in solid tumor settings (PMID 42247513). Inhibition of cathepsin B (CTSB) was reported to prevent trogocytosis — the transfer of CAR target antigen from tumor cells to T cells — thereby augmenting CAR-T function (PMID 42020353).

Pancreatic cancer, a notoriously immunosuppressive solid tumor, was addressed through a lipid nanoparticle (LNP) platform enabling pancreatic-targeted mRNA delivery of therapeutic cytokines; combining this approach with cancer vaccines or CAR-T therapy demonstrated superior antitumor efficacy in multiple preclinical models (PMID 41741655).

In Vivo CAR-T Engineering: Reducing Manufacturing Complexity

A major emerging research direction involves bypassing ex vivo manufacturing entirely by engineering CAR-T cells directly within the patient. A 2026 review (PMID 42064385) described how in vivo CAR-T engineering platforms are being developed to replace the current paradigm of autologous ex vivo product generation, potentially improving accessibility and reducing time-to-treatment. Multiple delivery platforms have been investigated. The HIV Envelope-Inspired T Cell Transfection-Enhancing (HITE) LNP platform (PMID 42012130) leveraged HIV envelope protein-derived mechanisms to improve mRNA delivery efficiency into primary T cells. β-Hydroxy thioether-derived ionizable lipids formulated into LNPs (PMID 42130331) showed spleen-tropic mRNA delivery and demonstrated the potential for in vivo CAR-T cell engineering. Optimization of in vivo CAR-T cell engineering for cancer immunotherapy was further reviewed with attention to vector design and delivery route (PMID 41490421).

Toxicities, Complications, and Long-Term Follow-Up

CAR-T therapy carries a well-characterized but expanding toxicity profile. Intractable diarrhea following BCMA-targeted CAR-T therapy (specifically ciltacabtagene autoleucel) for multiple myeloma was reported as a recently described complication with mortality rates of 36–50%, and ruxolitinib was evaluated as a therapeutic intervention for this refractory gastrointestinal toxicity (PMID 41592291). A rare ophthalmologic complication — cancer-associated retinopathy — was documented following CAR-T therapy in a case report (PMID 42060919). The CLARITY study protocol (PMID 42097661) was established as a longitudinal real-world surveillance program specifically designed to capture infection outcomes in recipients of CAR-T and bispecific antibody therapies, recognizing infections as a leading cause of non-relapse mortality. Respiratory viral infections were identified as a clinically important infectious complication following CD19 CAR-T cell therapy (PMID 42047272). A spectrum of post-CAR-T lymphoproliferative disorders was catalogued in a Nature Reviews Clinical Oncology analysis (PMID 41986503), which also highlighted emerging applications in solid tumors and autoimmune diseases. Long-term follow-up (LTFU) practices were critically examined (PMID 41974583), with data-informed optimization proposed to reduce burden on patients and providers while maintaining vigilance for late effects.

Healthcare Access and Reimbursement

Despite established clinical efficacy and demonstrated cost-effectiveness, significant disparities in time-to-reimbursement for CAR-T therapies persist across European healthcare systems (PMID 41705912). A health-economic analysis quantified patient gains attributable to faster reimbursement, emphasizing that delays in regulatory and payer approval translate into measurable clinical harm. Separately, secondary CNS involvement by LBCL was analyzed, with thiotepa-based autologous stem cell transplantation showing higher survival than CAR-T in propensity-score-matched comparisons in that specific subpopulation (PMID 41490516).

Key Publications

• Jun mRNA-LNP vaccine providing antigen and co-stimulation in the tumor microenvironment enhances CAR T cell function (CART-Vac). (Molecular therapy. Oncology, 2026, PMID 42256207): "Chimeric antigen receptor (CAR) T cell therapy has demonstrated limited efficacy in solid tumors due to the immunosuppressive tumor microenvironment (TME), which promotes T cell exhaustion and restricts CAR T cell expansion."
• Jun Modeling chimeric antigen receptor response at the single-cell level with conditional optimal transport. (Cell systems, 2026, PMID 42025164): "Chimeric antigen receptor (CAR) T cell therapy is a promising cancer immunotherapy; however, several challenges hamper its clinical efficacy."
• Jun Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma. (Blood advances, 2026, PMID 41894687): "Patients with large B-cell lymphoma who progress after second-line (2L) chimeric antigen receptor T cell (CAR T) therapy have an increasing number of post-CAR T treatment options available and should be considered for timely intervention if at high risk of CAR T failure."
• Jun Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activity. (Science advances, 2026, PMID 42247513): "Chimeric antigen receptor (CAR) T cell therapy faces many challenges against solid tumors including T cell exhaustion and poor CAR durability."
• May KLF4 overexpression in CAR T cells enhances antitumor potency by preventing exhaustion. (Journal for immunotherapy of cancer, 2026, PMID 42161404): "Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapy for patients with refractory or relapsed lymphoma or leukemia."
• May β-Hydroxy Thioether-Derived Ionizable Lipids for Spleen-Tropic mRNA Delivery and In Vivo Chimeric Antigen Receptor T Cell Engineering. (ACS nano, 2026, PMID 42130331): "Our study demonstrates the potential of the 113-AA-C8C14 LNP for in vivo CAR T cell therapy in the future."
• May HITE: HIV Inspired Lipid Nanoparticle Platform for CAR T Cell Engineering. (Nano letters, 2026, PMID 42012130): "Chimeric antigen receptor (CAR)-T therapy has led to remarkable advancements in the treatment of hematologic malignancies, encouraging extensive studies on its application to solid tumors and other diseases."
• May Clickable Universal Tumor-Antigen Equipping Strategy for Remedial Chimeric Antigen Receptor T Cells to Destroy Solid Tumors. (ACS nano, 2026, PMID 42013422): "Chimeric antigen receptor (CAR)-T cell therapy has shown striking efficacy in leukemia and lymphoma, but solid tumors remain largely refractory due to the scarcity of tumor-specific antigens and pervasive antigen heterogeneity, compounded by rapid CAR-T cell exhaustion that curtails their function and persistence."
• May Ruxolitinib for ciltacabtagene autoleucel-associated refractory diarrhea. (Blood, 2026, PMID 41592291): "Intractable diarrhea is a recently described complication following B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma with reported mortality rates of 36% to 50%."
• May Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma. (Blood, 2026, PMID 41701973): "In this retrospective analysis of 584 patients who received chimeric antigen receptor T-cell therapy for large B-cell lymphoma at 6 Australian centers, no association was found between time of infusion and outcome, accounting for confounders, suggesting minimal clinical impact of chronobiology in this setting."